Literature DB >> 16969493

Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.

Masao Chujo1, Takashi Miura, Yozo Kawano, Michiyo Miyawaki, Takayuki Imakiire, Yoji Hayashita, Katsunobu Kawahara.   

Abstract

Thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) are the major catabolic enzymes of 5-FU. In this study, we analyzed the concentration of TP and DPD in non-small cell lung cancer tissue by enzyme-linked immunosorbent assay. We measured the TP and DPD levels in 25 adenocarcinoma tissues and 25 squamous cell carcinoma tissues. The mean TP concentration in non-small cell lung cancer tissue was statistically higher than that of normal lung tissue as was the mean DPD concentration. The ratio of the TP level to DPD level in tumor tissue was higher in squamous cell carcinoma than in adenocarcinoma. No significant difference could be detected between the TP level, DPD level, or TP/DPD level and the tumor size or lymph node metastasis. In conclusion, chemotherapy with 5-FU may be more effective in squamous cell lung cancer patients than lung adenocarcinoma patients from the result of the ratio of TP to DPD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969493

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

Review 1.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

2.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

3.  A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.

Authors:  Hideki Tomimoto; Masaki Hanibuchi; Fumitaka Ogushi; Yoshio Okano; Tsutomu Shinohara; Hiroyuki Doi; Akiyoshi Yamamoto; Eiji Takeuchi; Akihiko Yamamoto; Masahiko Azuma; Hiroya Tada; Takanori Kanematsu; Soji Kakiuchi; Hisatsugu Goto; Seiji Yano; Yasuhiko Nishioka; Saburo Sone
Journal:  Oncol Lett       Date:  2011-03-10       Impact factor: 2.967

4.  The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.

Authors:  Trung The Van; Masaki Hanibuchi; Soji Kakiuchi; Seidai Sato; Takuya Kuramoto; Hisatsugu Goto; Atsushi Mitsuhashi; Yasuhiko Nishioka; Shin-Ichi Akiyama; Saburo Sone
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-16       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.